Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis.
PLoS OneSep 29, 2026 (epub)
Clinical ResearchOncology (Medical)
Yu Xiao, Jing Fu, Juan Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This Bayesian network meta-analysis evaluated the efficacy and safety of T-DXd compared to other HER2-targeted therapies in 3,339 patients with HER2-positive metastatic breast cancer after trastuzumab-based therapy. T-DXd demonstrated a higher confirmed overall response rate (ORR) than T-DM1, Lap-Cap, and PTN-Cap, but also showed increased odds of ILD/pneumonitis compared to T-DM1.
Key findings
- T-DXd had a higher confirmed ORR than T-DM1 (OR 6.31, 3.98-10.32).
- T-DXd showed less favorable PFS (HR 3.30, 95% CrI 2.06-5.28) compared to T-DM1.
- T-DXd had higher odds of ILD/pneumonitis than T-DM1 (OR 5.55, 2.79-12.16).
- Any-grade adverse event estimates did not indicate a safety advantage for T-DXd.
Why it matters
Understanding the comparative efficacy and safety of HER2-targeted therapies is crucial for optimizing treatment strategies in HER2-positive metastatic breast cancer, particularly in patients who have progressed after trastuzumab-based therapy.